A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis (Q37995500)

26 August 2017

A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis (English)

1 reference

26 August 2017

0 references

7

1 reference

26 August 2017

O Lesnyak

13

0 references

Nicola Napoli

object named as

N Napoli

17

0 references

author name string

S Lekamwasam

1

1 reference

26 August 2017

J D Adachi

2

1 reference

26 August 2017

D Agnusdei

3

1 reference

26 August 2017

J Bilezikian

4

1 reference

26 August 2017

S Boonen

5

1 reference

26 August 2017

F Borgström

6

1 reference

26 August 2017

A Diez Perez

8

1 reference

26 August 2017

R Eastell

9

1 reference

26 August 2017

L C Hofbauer

10

1 reference

26 August 2017

J A Kanis

11

1 reference

26 August 2017

B L Langdahl

12

1 reference

26 August 2017

R Lorenc

14

1 reference

26 August 2017

E McCloskey

15

1 reference

26 August 2017

O D Messina

16

1 reference

26 August 2017

B Obermayer-Pietsch

18

1 reference

26 August 2017

S H Ralston

19

1 reference

26 August 2017

P N Sambrook

20

1 reference

26 August 2017

S Silverman

21

1 reference

26 August 2017

M Sosa

22

1 reference

26 August 2017

J Stepan

23

1 reference

26 August 2017

G Suppan

24

1 reference

26 August 2017

D A Wahl

25

1 reference

26 August 2017

J E Compston

26

1 reference

26 August 2017

Joint IOF-ECTS GIO Guidelines Working Group

27

1 reference

26 August 2017

language of work or name

English

0 references

publication date

21 March 2012

1 reference

Osteoporosis International

26 August 2017

1 reference

26 August 2017

23

1 reference

26 August 2017

9

1 reference

26 August 2017

2257-2276

1 reference

https://scigraph.springernature.com/pub.10.1007/s00198-012-1958-1

26 August 2017

0 references

cites work

Management of glucocorticoid-induced osteoporosis

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: a consensus document of the Belgian Bone Club

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

Review and evaluation of the Dutch guidelines for osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

Prevention and treatment strategies for glucocorticoid-induced osteoporotic fractures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research (2004).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

Regional differences in treatment for osteoporosis. The Global Longitudinal Study of Osteoporosis in Women (GLOW).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

Oral corticosteroids and fracture risk: relationship to daily and cumulative doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

Use of oral corticosteroids and risk of fractures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

Use of inhaled corticosteroids and risk of fractures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

Fracture risk with intermittent high-dose oral glucocorticoid therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

Glucocorticoid-induced osteoporosis: pathophysiology and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

Minireview: live and let die: molecular effects of glucocorticoids on bone cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

Biphasic glucocorticoid-dependent regulation of Wnt expression and its inhibitors in mature osteoblastic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

Glucocorticoid enhances the expression of dickkopf-1 in human osteoblasts: novel mechanism of glucocorticoid-induced osteoporosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

Role of gap junction, hemichannels, and connexin 43 in mineralizing in response to intermittent and continuous application of parathyroid hormone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

Connexin 43 is required for the anti-apoptotic effect of bisphosphonates on osteocytes and osteoblasts in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

Glucocorticoids suppress bone formation via the osteoclast

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

FRAX and the assessment of fracture probability in men and women from the UK

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

The incidence and risk of hip fracture in Poland

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

A revised clinician's guide to the prevention and treatment of osteoporosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

Development and application of a Japanese model of the WHO fracture risk assessment tool (FRAX)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

European guidance for the diagnosis and management of osteoporosis in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

Case finding for the management of osteoporosis with FRAX--assessment and intervention thresholds for the UK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

FRAX(®) with and without bone mineral density

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

Official Positions for FRAX® Clinical Regarding Glucocorticoids: The Impact of the Use of Glucocorticoids on the Estimate by FRAX® of the 10 Year Risk of Fracture

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

Public health impact of adverse bone effects of oral corticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

Guidance for the adjustment of FRAX according to the dose of glucocorticoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

Interpretation and use of FRAX in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

Spine-hip discordance and fracture risk assessment: a physician-friendly FRAX enhancement.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

Guidelines for diagnosis and management of osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

Osteoporosis: burden, health care provision and opportunities in the EU: a report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

A comparison of case-finding strategies in the UK for the management of hip fractures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

Fracture risk assessment without bone density measurement in routine clinical practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

BMD, clinical risk factors and their combination for hip fracture prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

The cost-effectiveness of alendronate in the management of osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

Cost-effective osteoporosis treatment thresholds: the United States perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

Recommendations for the registration of agents for prevention and treatment of glucocorticoid-induced osteoporosis: an update from the Group for the Respect of Ethics and Excellence in Science.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

Alendronate in rheumatoid arthritis patients treated with methotrexate and glucocorticoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

Cyclical etidronate increases bone density in the spine and hip of postmenopausal women receiving long term corticosteroid treatment. A double blind, randomised placebo controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

A double blind placebo controlled study to determine the effects of intermittent cyclical etidronate on bone mineral density in patients on long-term oral corticosteroid treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

Teriparatide or alendronate in glucocorticoid-induced osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

Prevention and treatment of glucocorticoid-induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium, and alendronate plus calcium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

Long-term effect of 1 alpha-hydroxyvitamin D, calcium and thiazide administration on glucocorticoid-induced osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

Studies in cranial suture biology: Part I. Increased immunoreactivity for TGF-beta isoforms (beta 1, beta 2, and beta 3) during rat cranial suture fusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

Malabsorption of calcium in corticosteroid-induced osteoporosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

Optimal vitamin D status for the prevention and treatment of osteoporosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis. A randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

The role of vitamin D in corticosteroid-induced osteoporosis: a meta-analytic approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

Vitamin D analogs versus native vitamin D in preventing bone loss and osteoporosis-related fractures: a comparative meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

The cost effectiveness of bisphosphonates for the prevention and treatment of osteoporosis: a structured review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

Cost-effectiveness of the treatment and prevention of osteoporosis--a review of the literature and a reference model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

Cost-effectiveness of multifaceted evidence implementation programs for the prevention of glucocorticoid-induced osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

Individual fracture risk and the cost-effectiveness of bisphosphonates in patients using oral glucocorticoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

Cost-effectiveness of alendronate in the treatment of postmenopausal women in 9 European countries--an economic evaluation based on the fracture intervention trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

The cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAX.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

Bisphosphonate Use and the Risk of Subtrochanteric or Femoral Shaft Fractures in Older Women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

Trends in incidence of subtrochanteric fragility fractures and bisphosphonate use among the US elderly, 1996-2007.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

Bone turnover in bone biopsies of patients with low-energy cortical fractures receiving bisphosphonates: a case series.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

Low-energy femoral fractures associated with the long-term use of bisphosphonates: a case series from a Swiss university hospital

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

Severely suppressed bone turnover: a potential complication of alendronate therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

Severely suppressed bone turnover and atypical skeletal fragility

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

Bisphosphonate associated osteonecrosis of the jaw.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

Osteonecrosis of the jaw and bisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

Bisphosphonate-related osteonecrosis of the jaws: a single-center study of 101 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

Transplacental effects of bisphosphonates on fetal skeletal ossification and mineralization in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

Bisphosphonates in patients with autoimmune rheumatic diseases: Can they be used in women of childbearing age?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

Precision assessment and radiation safety for dual-energy X-ray absorptiometry: position paper of the International Society for Clinical Densitometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

What is the role of serial bone mineral density measurements in patient management?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

Clinical value of monitoring BMD in patients treated with bisphosphonates for osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

Development of an algorithm for using PINP to monitor treatment of patients with teriparatide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

Glucocorticoid excess affects cortical bone geometry in premenopausal, but not postmenopausal, women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

Fractures before menopause: a red flag for physicians

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

Mineral density of bone in the forearm in premenopausal women with fractured wrists

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

Estrogen status and heredity are major determinants of premenopausal bone mass

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

Clinical characteristics and medication use among premenopausal women with osteoporosis and low BMD: the experience of an osteoporosis referral center

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

Weight and body mass index at menarche are associated with premenopausal bone mass

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

Incidence of symptomatic vertebral fractures in women of childbearing age newly treated with high-dose glucocorticoid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

Age dependence of early symptomatic vertebral fracture with high-dose glucocorticoid treatment for collagen vascular diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

Major depression is a risk factor for low bone mineral density: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

Management of glucocorticoid-induced osteoporosis in patients with rheumatoid arthritis: rates and predictors of care in an academic rheumatology practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

A comparison of calcium, calcitriol, and alendronate in corticosteroid-treated premenopausal patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

Alendronate protects premenopausal women from bone loss and fracture associated with high-dose glucocorticoid therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

Risedronate for prevention of bone mineral density loss in patients receiving high-dose glucocorticoids: a randomized double-blind placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

A randomized, placebo-controlled trial of calcium supplementation for decreased bone density in corticosteroid-using patients with inflammatory bowel disease: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

Calcitriol does not prevent bone loss in patients with asthma receiving corticosteroid therapy: a double-blind placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

International variations in hip fracture probabilities: implications for risk assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

Atypical fractures and bisphosphonate therapy: A cohort study of patients with femoral fracture with radiographic adjudication of fracture site and features

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

Pregnancy outcome following in utero exposure to bisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

Effect of oral 1,25-dihydroxyvitamin D and calcium on glucocorticoid-induced osteopenia in patients with rheumatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

Bisphosphonate-Associated Osteonecrosis of the Jaw: Report of a Task Force of the American Society for Bone and Mineral Research

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

Do calcium plus vitamin D supplements increase cardiovascular risk?

21 January 2018

2 references

https://api.crossref.org/works/10.1007%2FS00198-012-1958-1

21 January 2018

12 December 2020

Effect of calcitriol on bone mineral density in premenopausal Chinese women taking chronic steroid therapy. A randomized, double blind, placebo controlled study

1 reference

12 December 2020

Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid-induced bone loss. Ciblos Study Group

1 reference

12 December 2020

Bisphosphonate Use and Atypical Fractures of the Femoral Shaft

1 reference

12 December 2020

High incidence rate of vertebral fractures during chronic prednisone treatment, in spite of bisphosphonate or alfacalcidol use. Extension of the alendronate or alfacalcidol in glucocorticoid-induced osteoporosis-trial

1 reference

12 December 2020

Prevention of corticosteroid-induced osteoporosis by alfacalcidol

1 reference

12 December 2020

Osteopenia in young hypogonadal women with systemic lupus erythematosus receiving chronic steroid therapy: a randomized controlled trial comparing calcitriol and hormonal replacement therapy

1 reference

12 December 2020

Glucocorticoid regulation of osteoclast differentiation and expression of receptor activator of nuclear factor-kappaB (NF-kappaB) ligand, osteoprotegerin, and receptor activator of NF-kappaB in mouse calvarial bones

1 reference

12 December 2020

Treatment of glucocorticoid-induced osteoporosis with alfacalcidol/calcium versus vitamin D/calcium

1 reference

12 December 2020

Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group

1 reference

12 December 2020

FRAX assessment of osteoporotic fracture probability in Switzerland

1 reference

12 December 2020

Efficacy of intermittent etidronate therapy for corticosteroid-induced osteoporosis in patients with diffuse connective tissue disease

1 reference

12 December 2020

Fat conversion of femoral marrow in glucocorticoid-treated patients: a cross-sectional and longitudinal study with magnetic resonance imaging

1 reference

12 December 2020

Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis

1 reference

12 December 2020

Risedronate, an effective treatment for glucocorticoid-induced bone loss in CKD patients with or without concomitant active vitamin D (PRIUS-CKD)

1 reference

12 December 2020

Prevention of bone loss with risedronate in glucocorticoid-treated rheumatoid arthritis patients

1 reference

12 December 2020

Clinical characteristics and etiologic factors of premenopausal osteoporosis in a group of Spanish women

1 reference

12 December 2020

Cyclical etidronate reverses bone loss of the spine and proximal femur in patients with established corticosteroid-induced osteoporosis

1 reference

12 December 2020

A clinical prediction rule to identify premenopausal women with low bone mass

1 reference

12 December 2020

Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study

1 reference

12 December 2020

Modulation of Dickkopf-1 attenuates glucocorticoid induction of osteoblast apoptosis, adipocytic differentiation, and bone mass loss

1 reference

12 December 2020

Which women should be selected for vertebral fracture assessment? Comparing different methods of targeting VFA

1 reference

12 December 2020

Associations of early premenopausal fractures with subsequent fractures vary by sites and mechanisms of fractures

1 reference

12 December 2020

Effect of intermittent cyclical etidronate therapy on corticosteroid induced osteoporosis in Japanese patients with connective tissue disease: 3 year followup.

1 reference

12 December 2020

Increased bone density in patients on steroids with etidronate

1 reference

12 December 2020

Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study

1 reference

12 December 2020

Osteoporosis and low bone mass in premenopausal and perimenopausal women

1 reference

12 December 2020

[A FRAX model for the assessment of fracture probability in Belgium]

1 reference

12 December 2020

Longterm effect of intermittent cyclical etidronate therapy on corticosteroid-induced osteoporosis in Japanese patients with connective tissue disease: 7-year followup

1 reference

12 December 2020

Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol, and calcitonin

1 reference

12 December 2020

Optimization of BMD measurements to identify high risk groups for treatment--a test analysis

1 reference

12 December 2020

Evaluation of the efficacy of etidronate therapy in preventing glucocorticoid-induced bone loss in patients with inflammatory rheumatic diseases. A randomized study

1 reference

12 December 2020

Corticosteroid osteoporosis: practical implications of recent trials

1 reference

12 December 2020

Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis

1 reference

12 December 2020

Requirements for DXA for the management of osteoporosis in Europe

1 reference

12 December 2020

Timing of Repeat BMD Measurements: Development of an Absolute Risk-Based Prognostic Model

1 reference

12 December 2020

Etidronate prevents high dose glucocorticoid induced bone loss in premenopausal individuals with systemic autoimmune diseases

1 reference

12 December 2020

Intermittent cyclical etidronate in the prevention of corticosteroid-induced bone loss

1 reference

12 December 2020

A Meta-Analysis of Prior Corticosteroid Use and Fracture Risk

1 reference

12 December 2020

Calcium and vitamin D for corticosteroid-induced osteoporosis

1 reference

12 December 2020

Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis

1 reference

12 December 2020

Intervention thresholds for osteoporosis in the UK

1 reference

12 December 2020

2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada.

1 reference

12 December 2020

Should postmenopausal women with rheumatoid arthritis who are starting corticosteroid treatment be screened for osteoporosis? A cost-effectiveness analysis

1 reference

12 December 2020

Vertebral fracture and bone mineral density in women receiving high dose glucocorticoids for treatment of autoimmune diseases.

1 reference

12 December 2020

Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate

1 reference

12 December 2020

Public health impact of adverse bone effects of oral corticosteroids

1 reference

12 December 2020

Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy

1 reference

12 December 2020

Guidelines for the diagnosis, prevention and treatment of osteoporosis

1 reference

12 December 2020

Effect of risedronate on high-dose corticosteroid-induced bone loss in patients with glomerular disease

1 reference

12 December 2020

The prevention of corticosteroid-induced bone loss with intermittent cyclical etidronate

1 reference

12 December 2020

Urinary deoxypyridinoline is a BMD-independent marker for prevalent vertebral fractures in postmenopausal women treated with glucocorticoid

1 reference

12 December 2020

Accurate assessment of precision errors: how to measure the reproducibility of bone densitometry techniques

1 reference

12 December 2020

High fracture probability with FRAX® usually indicates densitometric osteoporosis: implications for clinical practice

1 reference

12 December 2020

Prophylactic use of alfacalcidol in corticosteroid-induced osteoporosis

1 reference

12 December 2020

The outcome of pregnancy following pre-pregnancy or early pregnancy alendronate treatment

1 reference

12 December 2020

A cost effectiveness analysis of calcium and vitamin D supplementation, etidronate, and alendronate in the prevention of vertebral fractures in women treated with glucocorticoids.

1 reference

12 December 2020

Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis

1 reference

12 December 2020

10.1007/S00198-012-1958-1

Identifiers

DOI

1 reference

release_melmm4ea5zhbtnsgwyxgsjz55u

26 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/melmm4ea5zhbtnsgwyxgsjz55u

24 November 2022

mapped directly with Wikidata item

1 reference